Ceribell, Inc. is a commercial-stage medical technology company. It is focused on transforming the diagnosis and management of patients with serious neurological conditions. It has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Point-of-Care EEG enables early detection and management of suspected seizure patients, promoting precise patient care and hospital-wide efficiencies. Its Clarity AI algorithm interprets EEG in real-time, provides bedside alerts and continuous monitoring for status epilepticus. The Ceribell EEG Portal makes it easy to remotely review EEG in real-time with pre-annotated EEG insights.
높은 성장
회사의 매출은 지난 3년간 꾸준히 성장해왔으며, 연평균 152.47%의 증가율을 기록했습니다.
성장 중
회사는 성장 단계에 있으며, 최신 연간 수익은 미화 65.44M에 달합니다.
과대 평가된
회사의 최신 PE은 -8.40로, 최근 3년 기준 높은 백분위 범위에 속합니다.
기관 매수
최신 기관 보유 주식 수는 30.96M주이며, 전 분기 대비 10.03% 증가했습니다.
PRFDX가 보유
스타 투자자 PRFDX이(가) 이 주식 1.10K주를 보유하고 있습니다.